BIOGEN IDEC
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $4 billion in annual revenues.
BIOGEN IDEC
Industry:
Biotechnology Health Care Neuroscience Therapeutics
Founded:
1978-01-01
Address:
Weston, Massachusetts, United States
Country:
United States
Website Url:
http://www.biogen.com
Total Employee:
5001+
Status:
Active
Contact:
(781) 464-2000
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Content Delivery Network Domain Not Resolving Apache Mobile Non Scaleable Content Euro Organization Schema IPv6
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
MBF Bioscience
MBF Bioscience is a biotechnology firm that provides imaging software for stereology, neuron reconstruction, and image analysis.
Current Advisors List
Board_member
2020-09-01
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
2010-01-01
Board_member
Current Employees Featured
Deborah Glasser Associate Director - BG12 HCP Marketing @ Biogen Idec
Associate Director - BG12 HCP Marketing
2011-10-01
Jaren Landen Early Alzheimer's Disease Head @ Biogen Idec
Early Alzheimer's Disease Head
2020-10-01
David Kolwyck Director Manufacturing Science - Raw Materials @ Biogen Idec
Director Manufacturing Science - Raw Materials
2014-12-01
Elodie Cramer Head of Strategic Sourcing @ Biogen Idec
Head of Strategic Sourcing
2013-06-01
Yizhou Zhou Head of Cell Line Technology, Gene Therapy Development @ Biogen Idec
Head of Cell Line Technology, Gene Therapy Development
2022-01-01
Georgia Mitsi GM Mental Health & VR solutions @ Biogen Idec
GM Mental Health & VR solutions
2021-06-01
Firoz Antia Executive Director, Head of Oligonucleotide Development @ Biogen Idec
Executive Director, Head of Oligonucleotide Development
2021-12-01
Baohong Zhang Head of Genome Informatics @ Biogen Idec
Head of Genome Informatics
2018-08-01
Priya Singhal Head, SVP, Global Safety & Regulatory Sciences @ Biogen Idec
Head, SVP, Global Safety & Regulatory Sciences
2020-02-01
Joel Schwartz Sr. Manager @ Biogen Idec
Sr. Manager
2018-08-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-03-04 | Nightstar Therapeutics | Nightstar Therapeutics acquired by Biogen Idec | N/A |
| 2017-05-18 | Remedy Pharmaceuticals | Remedy Pharmaceuticals acquired by Biogen Idec | 120 M USD |
| 2015-01-11 | Convergence Pharmaceuticals | Convergence Pharmaceuticals acquired by Biogen Idec | 675 M USD |
| 2014-02-14 | Stromedix | Stromedix acquired by Biogen Idec | 75 M USD |
| 2013-02-01 | Tysabri | Tysabri acquired by Biogen Idec | N/A |
| 2007-01-04 | Syntonix Pharmaceuticals | Syntonix Pharmaceuticals acquired by Biogen Idec | 120 M USD |
| 2006-05-31 | Fumapharm | Fumapharm acquired by Biogen Idec | N/A |
| 2006-05-03 | Conforma Therapeutics | Conforma Therapeutics acquired by Biogen Idec | 150 M USD |
| 2003-06-24 | IDEC Pharmaceuticals | IDEC Pharmaceuticals acquired by Biogen Idec | 6.4 B USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-09-08 | Autobahn Therapeutics | Biogen Idec investment in Venture Round - Autobahn Therapeutics | 32.7 M USD |
| 2020-11-27 | SAGE Therapeutics | Biogen Idec investment in Post-IPO Equity - SAGE Therapeutics | 650 M USD |
| 2020-06-11 | Autobahn Therapeutics | Biogen Idec investment in Series B - Autobahn Therapeutics | 76 M USD |
| 2020-01-13 | CAMP4 Therapeutics | Biogen Idec investment in Venture Round - CAMP4 Therapeutics | 15 M USD |
| 2018-06-28 | Samsung Bioepis | Biogen Idec investment in Venture Round - Samsung Bioepis | 748.6 B KRW |
| 2017-10-25 | Neurimmune Holding | Biogen Idec investment in Venture Round - Neurimmune Holding | 150 M USD |
| 2017-03-30 | Solid Biosciences | Biogen Idec investment in Series C - Solid Biosciences | 50 M USD |
| 2016-01-06 | Rodin Therapeutics | Biogen Idec investment in Series B - Rodin Therapeutics | 17.3 M USD |
| 2014-06-17 | True North Therapeutics | Biogen Idec investment in Series A - True North Therapeutics | 22 M USD |
| 2014-03-17 | Ataxion | Biogen Idec investment in Series A - Ataxion | 17 M USD |
Newest Events participated
Participated in 14th Annual International Pediatric Orthopaedic Symposium
on 2017-11-28 as sponsor
Participated in North Carolina Science Festival
on 2015-04-10 as sponsor
Official Site Inspections
http://www.biogen.com
- Host name: ec2-54-204-187-63.compute-1.amazonaws.com
- IP address: 54.204.187.63
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Biogen Idec"
Leadership - Biogen
Meet our executive leadership team. Inspired by the science: Mother, daughter reflect on 50 plus years at BiogenSee details»
Company | Biogen
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized …See details»
Biogen - Wikipedia
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from …See details»
Biogen Canada
Biogen Canada was established in Mississauga, Ontario in April 1998 and has been proudly serving Canadians for more than 25 years. Biogen Canada is a trusted leader in the fields of multiple sclerosis (MS) and spinal muscular …See details»
Biogen - Crunchbase Company Profile & Funding
Biogen is a biotechnology company engaged in the development of innovative therapies for neurological and neurodegenerative diseases. Biogen is developing a pipeline of possible medicines in neurology, neuropsychiatry, specialized …See details»
Biogen - The Org
Biogen is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.See details»
Org Chart Biogen - The Official Board
Jan 13, 2025 The organizational chart of Biogen displays its 90 main executives including Christopher Viehbacher, Susan Alexander, Wolfram Schmidt and Eileen Rivera. Toggle …See details»
Biogen - Leadership Team - The Org
The Leadership Team at Biogen is responsible for setting the strategic direction and operational oversight of the company. Comprising executives from various domains such as research, …See details»
Investor Relations | Biogen
Mar 24, 2025 Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for …See details»
Biogen
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized …See details»
Biogen Announces Plans for New Global Headquarters and …
Mar 24, 2025 Biogen’s history in the region can be traced back to the early 1980s when it established its research facility and headquarters in Kendall Square. Cambridge will remain …See details»
Mission and Culture - Biogen
Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our …See details»
Biogen Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. It offers …See details»
Science & Innovation - Biogen
Biogen is dedicated to enhancing the lives of those with SMA and their families through ongoing research, removing barriers to access and providing support programs. In December 2017, …See details»
Biogen to Move Global Headquarters to Kendall Commons in 2028
5 days ago Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new building in Kendall Square in 2028, consolidating its …See details»
Biogen Inc - Encyclopedia.com
May 23, 2018 Biogen is a corporate and scientific leader in this rapidly changing environment. 1990s and Beyond: Moving from Licensor to Manufacturer and Marketer. Biogen benefited in …See details»
Biogen - Crunchbase Company Profile & Funding
Biogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. Founded …See details»
biogen - Org Chart | PharmaKonnect
Leverage pharma company-based org charts to gain customized and actionable insights into these pharma giants. Home/ Biogen. Biogen +follow. 781 464 2000. 1 833 425 9360. 1 800 …See details»
Biogen plots new global headquarters in Kendall Square
Mar 24, 2025 Biogen on Monday announced plans for a new global headquarters just steps away from its current one.. The big biotechnology firm has signed a 15-year lease for …See details»
Biogen to consolidate operations in MIT’s first Kendall ... - MIT News
Mar 24, 2025 Biogen announced that it will centralize operations in a new facility at 75 Broadway in MIT’s Kendall Common development. The move, to take place in 2028, highlights the …See details»